LENZ Therapeutics Income Statement (2020-2026) | LENZ

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
0.73M8.30M4.13M8.29M8.32M8.31M8.32M8.31M8.28M8.28M8.29M4.72M25.87M27.50M21.28M27.54M28.50M28.59M31.34M31.35M
Revenue & cost
Revenue (Quarter)
5.00M12.50M-12.50M1.90M
Gross Profit (Quarter)
0.82M
Operating items
Research & Development (Quarter)
12.67M8.68M11.21M18.25M17.78M18.30M18.46M10.32M12.64M17.00M19.54M10.54M6.95M6.45M5.87M5.82M9.06M3.79M
Selling, General & Administrative (Quarter)
4.87M5.92M7.74M7.71M9.00M7.85M8.29M2.29M2.32M2.86M5.45M5.55M7.41M6.49M9.36M11.11M12.80M27.60M0.50M44.96M
Restructuring Costs (Quarter)
5.30M0.20M
Other Operating Expenses (Quarter)
-0.07M39.55M1.08M
Operating Expenses (Quarter)
17.53M14.60M18.94M25.96M26.78M26.15M26.75M12.62M14.96M19.86M24.99M16.09M14.35M12.95M15.22M16.93M21.86M31.39M40.05M46.04M
Operating Income (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M
EBIT (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M
Non-operating items
Interest & Investment Income (Quarter)
-0.31M-0.72M-0.56M0.55M-0.01M0.01M2.19M-0.01M-0.06M2.74M-0.33M2.32M-0.09M2.20M0.01M2.64M
Other Non Operating Income (Quarter)
0.00M0.01M0.01M0.12M0.84M1.47M2.15M-0.05M-0.02M-0.10M0.27M-1.35M1.64M-0.01M0.01M-0.01M0.20M-0.01M-0.42M0.00M
Non Operating Income (Quarter)
0.00M0.01M0.01M0.12M0.84M1.47M2.15M-0.05M0.23M0.98M1.12M-0.56M4.10M2.73M2.57M2.31M2.44M2.19M2.57M2.65M
Net income details
EBT (Quarter)
-130.53M-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.41M-16.70M-35.89M-42.21M
Tax Provisions (Quarter)
0.00M0.50M0.00M
Profit After Tax (Quarter)
-17.53M-14.59M-18.93M-25.84M-25.94M-25.25M-24.05M-12.67M-14.73M-18.88M-23.69M-16.65M-10.25M-9.63M-13.17M-14.62M-14.91M-16.51M-35.85M-41.49M
Income from Continuing Operations (Quarter)
-130.53M-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M
Consolidated Net Income (Quarter)
-130.53M-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M
Income towards Parent Company (Quarter)
-130.53M-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M
Net Income towards Common Stockholders (Quarter)
-130.53M-54.99M-20.94M-27.58M-636.45M-34.23M-28.35M-17.43M-49.79M-53.23M-18.18M-16.14M-10.25M-10.21M-12.65M-15.91M-14.91M-16.70M-35.90M-42.21M
Additional items
EPS (Basic) (Quarter)
-179.61-7.29-5.07-3.58-81.63-4.34-3.62-2.18-6.14-6.51-2.23-3.42-0.40-0.38-0.59-0.58-0.53-0.59-1.25-1.35
EPS (Diluted) (Quarter)
-179.61-7.29-5.07-3.58-81.63-4.34-3.62-2.18-6.14-6.51-2.23-3.42-0.40-0.38-0.59-0.58-0.53-0.59-1.25-1.35
Shares Outstanding (Quarter)
0.73M7.54M4.13M7.72M7.80M7.89M7.84M7.98M8.11M8.18M8.15M4.72M25.61M27.17M21.28M27.53M28.08M28.54M28.81M31.35M
Shares Outstanding (Diluted) (Quarter)
0.73M7.54M4.13M7.72M7.80M7.89M7.84M7.98M8.11M8.18M8.15M4.72M25.61M27.17M21.28M27.53M28.08M28.54M28.81M31.35M
EBITDA (Quarter)
-17.53M-14.60M-18.94M-25.96M-26.78M-26.15M-26.75M-12.62M-14.96M-19.86M-24.99M-16.09M-14.35M-12.95M-15.22M-16.93M-16.86M-18.89M-38.46M-44.13M
Interest Expenses (Quarter)
113.00M40.39M2.00M1.32M608.95M7.52M2.14M4.82M34.81M33.38M-4.62M0.04M1.68M1.60M55.53M1.30M1.15M1.03M0.03M0.72M
Tax Rate (Quarter)
-0.01-3.47-0.01